15167 results for "cancer studies using rna-seq"

in 18.50 milliseconds.

• Bulk tumor RNAseq of bladder cancer patients

  RNAseq fastq files from 611 bulk pre-treatment tumors from two indications: metastatic urothelial bladder cancer patients (IMvigor210) and metastatic renal cell carcinoma (IMmotion150)

  Dataset EGAD00001006960

• Geographic and age-related variations in mutational processes in colorectal cancer - patient metadata files (Mutographs)

  Geographic and age-related variations in mutational processes in colorectal cancer - patient metadata files (Mutographs)

  Dataset EGAD00001015437

• Ovarian cancer organoid biobank - followup

  WGS of more samples in the ovarian cancer organoid biobank dataset.

  Dataset EGAD00001005707

• The complexity of tobacco smoke induced mutagenesis in head and neck cancer - sequence data (Mutographs)

  The complexity of tobacco smoke induced mutagenesis in head and neck cancer - sequence data (Mutographs)

  Dataset EGAD00001015386

• Geographic and age-related variations in mutational processes in colorectal cancer - copy number variants (Mutographs)

  Geographic and age-related variations in mutational processes in colorectal cancer - copy number variants (Mutographs)

  Dataset EGAD00001015487

• Colorectal organoids and tumoroids - pulldown

  Targeted capture of cancer gene panel bait set in single cell derived organoids from colon tissue and colorectal cancer from 1 patient.

  Dataset EGAD00001001208

• Transcriptome of biliary tract cancer

  Fastq files of RNAseq of 182 samples of biliary tract cancer

  Dataset EGAD00001001693

• MSI_Cancer_Models___WGS

  The study will use whole genome sequencing to aid in define determinants of WRN dependency in MSI Cancer models.

  Study EGAS00001004178

• Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive, HER2-negative breast cancer patients.

  This study aims to evaluate the efficacy of the combination of olaparib, durvalumab, and fulvestrant for the treatment of patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer with BRCA gene alterations or alterations of genes involved in HRR or MSI status, in terms of the progression-free survival rate (PFSR) at 24 weeks.

  Study EGAS50000001166

• SDH_deficient_renal_tumours___RNA_

  Succinate dehydrogenase (SDH) deficient renal cancers are a rare and understudied subtype of renal cancer. As such they represent an unmet need in kidney cancer research. Here, we seek to describe the genomics and transcriptomics of SDH deficient renal cancers by sequencing five such tumours. We document their mutational burden, define driver mutations, demonstrate typical patterns of structural variants, and estimate the cell of origin and cellular composition.

  Study EGAS00001004103

• Spontaneous mutations in the single TTN gene represent high tumor mutation burden

  Tumor mutation burden (TMB) is an emerging biomarker, whose calculation requires targeted sequencing of many genes. We investigated if the measurement of mutation counts within a single gene is representative of TMB. Whole exome sequencing (WES) data from the pan-cancer cohort (n=10,224) of TCGA, and targeted sequencing (tNGS) and TTN gene sequencing from 24 colorectal cancer samples (AMC cohort) were analyzed.

  Study EGAS00001004009

• Sequence data from stage I of the CCTG BR.36 ctDNA-directed, multi-center phase II study of molecular response adaptive immunotherapy in non-small cell lung cancer

  The dataset for the study "Early ctDNA molecular response captures therapeutic response in the first stage of CCTG BR.36 ctDNA-directed, multi-center phase II study of molecular response adaptive immunotherapy in non-small cell lung cancer", includes 134 bam files from hybrid capture targeted error-correction next-generation sequencing (PGDx Elio plasma resolve) from plasma cell-free DNA and matched white blood cell DNA from 35 individuals with non-small cell lung cancer on the BR.36 trial, alongside 11 bam files from targeted next generation sequencing (PGDx Elio tissue complete) of tumor DNA from 11 individuals with non-small cell lung cancer on the BR.36 trial.

  Dataset EGAD00001011359

• Microarray_cases

  CASE SAMPLES USING Affymetrix SNP6.0 technology (Thermo Fisher Scientific company): OncoScan FFPE Assay Kit was used for FFPE tissue samples (designed for degraded DNA) and the Cytoscan HD Array Kit was used for the fresh-frozen tissues

  Dataset EGAD00010002034

• Nanopore sequencing of brain tumor tissue obtained by cavitating ultrasonic aspiration

  This dataset contains 21 pediatric brain tumor cases which where obtained during surgery using a cavitating ultrasonic aspiration and submitted to nanopore whole genome sequencing.

  Dataset EGAD50000000269

• OXEL pilot WES data

  This dataset contains aligned BAM files from whole-exome sequencing of 29 patients from the Oxel pilot study. Alignment to GRCh38 reference genome was performed using the BWA aligner.

  Dataset EGAD50000000327

• H3Africa ACEGID H3Africa Array Genotype

  SNP Genotyping for Lassa Fever cases and population controls from Nigeria and Sierra Leone using Illumina H3Africa array version 1

  Dataset EGAD00010002510

• Whole genome sequencing profiling of patient-derived organoids (PDO)

  Whole genome sequencing profiling of 41 PDAC patient-derived organoids (PDO) - WGS unmapped reads, sequenced using NovaSeq 6000, 15x coverage 160 million reads per sample.

  Dataset EGAD50000000280

• N2M2 methylation array data

  Methylation profiling of 228 samples, using the approach described in "Molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (N2M2/NOA-20 phase I/IIa umbrella trial)"

  Dataset EGAD00010002747

• WES_dataset1

  Fourteen MEITLs and one EATL previously had been sequenced using the SureSelectXT Target Enrichment System (Agilent Technologies, Santa Clara, CA, USA).

  Dataset EGAD50000001620

• LBC1921 gvcfs

  297 members of the LBC1921 were sequenced using the Illumina HiSeq X platform. This dataset contains the gvcfs.

  Dataset EGAD00001006416

• Copy Number Variation using Affymetrix Optima Array

  Diagnostic yield of affymetrix optima microarray in patients with non-syndromic autism spectrum disorders in India.

  Study EGAS00001006439

• 666PG SNVs

  SNV calls generated using SomaticSniper in VCF format from the CPCGene 666PG study

  Dataset EGAD00001006148

• Whole genome sequencing in myasthenia gravis

  This dataset contains whole genome sequencing data on 25 individuals with myasthenia gravis. The data was generated using Illumina sequencing technology and is presented as BAM files for each sample.

  Dataset EGAD00001005262

• 666PG indels

  Indel calls generated using Pindel in VCF format from the CPCGene 666PG study

  Dataset EGAD00001006147

• Macrophage response in term and preterm infants

  The data set comprises 48 samples from term and preterm infants. Expression profiles were generated using different stimuli (O2 3%, 21%, 65%; LPS stimulation).

  Dataset EGAD00001006885